<code id='704DB4875F'></code><style id='704DB4875F'></style>
    • <acronym id='704DB4875F'></acronym>
      <center id='704DB4875F'><center id='704DB4875F'><tfoot id='704DB4875F'></tfoot></center><abbr id='704DB4875F'><dir id='704DB4875F'><tfoot id='704DB4875F'></tfoot><noframes id='704DB4875F'>

    • <optgroup id='704DB4875F'><strike id='704DB4875F'><sup id='704DB4875F'></sup></strike><code id='704DB4875F'></code></optgroup>
        1. <b id='704DB4875F'><label id='704DB4875F'><select id='704DB4875F'><dt id='704DB4875F'><span id='704DB4875F'></span></dt></select></label></b><u id='704DB4875F'></u>
          <i id='704DB4875F'><strike id='704DB4875F'><tt id='704DB4875F'><pre id='704DB4875F'></pre></tt></strike></i>

          entertainment

          entertainment

          author:hotspot    Page View:3621
          A photo of Robert Blum speaking at the STAT Summit West on May 16, 2024
          Cytokinetics CEO Robert Blum spoke last week at a talk during STAT’s Breakthrough Summit West in San Francisco. Sarah Gonzalez for STAT

          Cytokinetics, a drugmaker that is expected to soon launch a promising new heart therapy called aficamten, said Wednesday that it had agreed to pay biotech firm Royalty Pharma a higher royalty on the medicine in return for up to $575 million, which will be used to fund the marketing of the drug and Cytokinetics’ ongoing research and development efforts.

          Cytokinetics shares fell nearly 10% in after-hours trading after the announcement, which investors viewed as lowering the odds that the company will be purchased by a larger pharmaceutical company.

          advertisement

          The firm also said that it would be raising $500 million through a stock sale. 

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          focus

          Dobbs anniversary: the lost opportunity of abortion as health care
          Dobbs anniversary: the lost opportunity of abortion as health care

          NathanHoward/GettyImagesReflectingonthisfirstanniversaryoftheSupremeCourt’sdecisioninDobbstooverturn

          read more
          Key House Republican on health care plans exit from Congress
          Key House Republican on health care plans exit from Congress

          Rep.CathyMcMorrisRodgersannouncedherplanstoleaveCongressattheendof2024.AnnaMoneymaker/GettyImagesWAS

          read more
          After affirmative action ruling, medical educators look to 'holistic review'
          After affirmative action ruling, medical educators look to 'holistic review'

          AnnaMoneymaker/GettyImagesAfterhavingadaytoreadthroughtheSupremeCourt’sdecisiononaffirmativeaction,s

          read more

          Merck drug for rare lung condition set for approval in U.S.

          AdobeTheFoodandDrugAdministrationisexpectedtoapproveMerck’sdrugtotreatararelungdisordercalledpulmona